Sales of Yescarta, Kite’s sole approved therapy, fell slightly in the third quarter to $118 million. Winning FDA approval could provide a boost to Gilead’s cell therapy business, which is yet to deliver the sales to justify the $11.9 billion takeover of Kite. All the participants in Kite’s trial had received a BTK inhibitor, plus an average of two other therapies, prior to treatment with KTE-X19. YESCARTA, the Yescarta Logo, KITE KONNECT, the Kite Konnect Logo, KITE. The price is well below that of the first. You are encouraged to report negative side effects of prescription drugs to the FDA. ![]() Use of BTK inhibitors such as Imbruvica has improved response rates in MCL patients in recent years, but the prognosis for people who progress after treatment with these drugs is poor. Gilead, which recently acquired Kite Pharma, said the list price for Yescarta, which is to be administered just once to each patient, would be 373,000. The data suggest KTE-X19 can find a role in the MCL treatment pathway. Fosun Kite is a joint venture between Fosun Pharma. In the subset of patients with at least 24 months of follow-up, 43% stayed in remission without additional therapy. (Fosun Kite) today inaugurated a manufacturing facility for cancer cell therapy in Zhangjiang, Shanghai. Food and Drug Administration (FDA) has approved Yescarta (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of. More than half of patients had an ongoing response at the cutoff, which featured a median follow-up of 12.3 months. SANTA MONICA, Calif.-(BUSINESS WIRE)- Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Kite also shared data on the durability of the responses. The objective response rate came in at 93%, suggesting KTE-X19 works in a heavily pretreated population. At ASH, Kite revealed 67% of the 60 patients treated with KTE-X19 in a phase 2 trial had a complete response. ![]() The review will go over phase 2 results Kite shared at the American Society of Hematology (ASH) annual meeting.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |